Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Use of dextromethorphan and an oxidase inhibitor to treat dermatitis|
|Abstract:||This invention discloses a method for treating human patients suffering from dermatitis, particularly severe dermatitis which does not respond adequately to non-prescription drugs. Such patients are treated using dextromethorphan (DM), an antitussive agent normally used in cough syrup. If the patient is a so-called "extensive metabolizer," an antioxidant drug (such as quinidine) can be coadministered to inhibit the DM-degrading activity of debrisoquin hydroxylase, an enzyme that will rapidly convert DM into its metabolite, dextrorphan. This treatment has been shown to be highly effective in treating severe dermatitis, and in most patients this drug combination causes no significant adverse side effects.|
|Inventor(s):||Smith; Richard A. (La Jolla, CA)|
|Filing Date:||Sep 02, 1993|
|Claims:||1. A method of treating dermatitis in humans, comprising administering to a patient suffering from dermatitis which does not respond adequately to non-prescription drugs a therapeutically effective quantity of a drug selected from the group consisting of: |
(a) dextromethorphan, and
(b) pharmaceutically acceptable salts and analogs of dextromethorphan which are effective in treating dermatitis.
2. The method of claim 1 wherein the patient being treated is classified as a "poor metabolizer" whose enzymes cannot rapidly convert dextromethorphan into dextrorphan.
3. A method of treating dermatitis in a human patient, comprising administering to a patient who is an extensive metabolizer of dextromethorphan, and who is suffering from dermatitis which does not respond adequately to non-prescription drugs, a combination of dextromethorphan or a pharmaceutically acceptable salt or analog thereof, and an antioxidant drug which significantly inhibits enzymatic oxidation of dextromethorphan in that patient and which is pharmaceutically acceptable to that patient, at therapeutically effective dosages for each compound which allow the antioxidant drug to significantly inhibit enzymatic oxidation of the dextromethorphan in the body of the patient and which allow the dextromethorphan or the salt or analog thereof to provide substantial relief from the dermatitis.
4. The method of claim 3 wherein the antioxidant drug is selected from the group consisting of quinidine, quinine, and fluoxetine, and pharmaceutically acceptable salts and analogs thereof which inhibit the enzymatic degradation of dextromethorphan.
5. The method of claim 4 wherein quinidine is administered to a patient at a dosage not exceeding about 150 milligrams per day.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.